03.12.2020 Issuance of a 4th tranche of €1.5 million of notes convertible into new shares DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
19.11.2020 DEINOVE signs an Evaluation and Technology Development License with DSM DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment...
12.11.2020 DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the protocol of the ongoing Phase...
01.10.2020 2020 Half-year results: Stronger financial position and research programs moving forward despite the international context Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
15.07.2020 DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...
17.06.2020 Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020 Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships • Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
29.04.2020 2019 Annual results: A year of important milestones in both Antibiotics and Cosmetics activities Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...
23.04.2020 Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion...
03.04.2020 Issuance of a 2nd tranch of €1 million of notes convertible into new shares DEINOVE immediately strengthens its cash position by €1 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses...